Fibromuscular Dysplasia of the Vertebral Artery
For fibromuscular dysplasia (FMD) of the vertebral artery, initiate antiplatelet therapy with aspirin 75-325 mg daily as first-line treatment, reserving endovascular angioplasty for symptomatic patients with posterior circulation ischemia who fail medical management.
Initial Diagnostic Approach
When FMD of the vertebral artery is suspected, obtain MRA or CTA imaging rather than ultrasound for definitive diagnosis 1. These modalities are superior for evaluating vertebral artery pathology and identifying the characteristic "string of beads" appearance or focal stenosis patterns of FMD.
Key imaging considerations:
- CTA or MRA should be part of the initial evaluation for any patient with posterior circulation symptoms 1
- Consider catheter-based angiography only when noninvasive imaging fails to define the location or severity of stenosis in patients who are revascularization candidates 1
- Given that FMD is a polyvascular disease, panvascular imaging from head-to-pelvis is recommended upon diagnosis to screen for involvement in other arterial beds 2, 3
Medical Management (First-Line)
All patients with vertebral artery FMD should receive:
Antiplatelet therapy: Aspirin 81-325 mg daily is the cornerstone of treatment 1, 4, 5. This Class I recommendation (Level of Evidence B) applies to all patients with vertebral artery disease to prevent MI and other ischemic events.
Alternative antiplatelet regimens if symptomatic despite aspirin:
Risk factor modification: Apply the same atherosclerotic risk reduction strategies used for carotid disease, including lifestyle modifications 1
Important caveat: While the guidelines focus on atherosclerotic vertebral disease, the research evidence confirms that antiplatelet therapy represents the cornerstone for cerebrovascular FMD specifically 4, 5.
Indications for Intervention
Endovascular angioplasty (balloon angioplasty alone, without stenting) is the preferred intervention when revascularization is necessary 4, 2, 5. However, the evidence for intervention in vertebral FMD specifically is limited.
Consider revascularization when:
- Patient has symptomatic posterior circulation ischemia (TIA or stroke) despite optimal medical therapy
- Clear attribution of symptoms to vertebral artery stenosis can be established
- Patient is at acceptable surgical/procedural risk
Critical evidence limitations: The 2011 guidelines note that for vertebral artery stenosis in general, there is insufficient evidence from randomized trials demonstrating that endovascular management is superior to medical management 6, 1. The CAVATAS trial included only 16 patients with vertebral artery stenosis and showed no difference between stenting and medical therapy at 8 years 6.
Surgical Options (Rarely Indicated)
Surgery is rarely performed for vertebral artery disease 6, 1. When symptoms can be clearly attributed to vertebral artery occlusive disease and medical/endovascular options have failed, surgical approaches include:
- Trans-subclavian vertebral endarterectomy
- Vertebral artery transposition to the common carotid artery
- Reimplantation with vein graft extension
Reported outcomes show perioperative mortality of 0-4% for proximal reconstruction and 2-8% for distal reconstruction 6, 1, but these data are primarily from atherosclerotic disease, not FMD specifically.
Follow-Up Strategy
Serial noninvasive imaging (CTA or MRA) is reasonable at intervals similar to carotid revascularization protocols 1:
- For symptomatic patients: Monitor disease progression and exclude new lesions
- For patients who undergo revascularization: Surveillance imaging to detect restenosis
- Typical intervals: 6 months, 1 year, then annually if stable
Screen for complications specific to FMD:
- Arterial dissection (vertebral or other beds)
- Aneurysm formation (intracranial and extracranial) 7, 2, 5
- Involvement of other arterial territories 2, 3, 8
Common Pitfalls to Avoid
Do not assume asymptomatic vertebral FMD requires intervention: Asymptomatic patients should receive antiplatelet therapy and surveillance only 5
Avoid stenting as first-line endovascular treatment: Balloon angioplasty alone is preferred for FMD; stenting should be reserved for complications or failure of angioplasty 4, 2
Do not overlook associated intracranial aneurysms: FMD is associated with increased prevalence of brain aneurysms, requiring screening 7, 2
Recognize that vertebral intervention carries significant risk: Periprocedural neurological complications occur in 5.5% of proximal vertebral interventions and up to 24% for distal vertebrobasilar procedures 6, 1
Do not treat based on imaging alone: Symptoms must be clearly attributable to the vertebral lesion before considering intervention, as restenosis after intervention (26% at 12 months) does not consistently correlate with recurrent symptoms 6, 1
Special Considerations for FMD
Unlike atherosclerotic vertebral disease, FMD may be caused by inherent arterial wall fragility that progresses to aneurysm formation under hemodynamic stress 7. This underscores the importance of:
- Comprehensive vascular imaging to identify all affected territories
- Long-term surveillance even in asymptomatic patients
- Multidisciplinary care involving neurology, vascular surgery, and interventional radiology 8